Summary
Boston Scientific Corporation (BSX) has filed an 8-K report detailing key updates to its executive compensation programs for the 2016 performance year. The company's Board of Directors, upon recommendation from its Compensation Committee, has approved the 2016 Annual Bonus Plan and two new performance share programs: the 2016 Total Shareholder Return Performance Share Program (TSR PSP) and the 2016 Free Cash Flow Performance Share Program (FCF PSP). These plans are designed to incentivize executive performance and align compensation with shareholder interests and key business objectives.
Key Highlights
- 1Approval of the 2016 Annual Bonus Plan, which will base incentives on corporate performance metrics including adjusted earnings per share and global sales (on a constant currency basis).
- 2The 2016 Annual Bonus Plan includes a cap on the total bonus pool if global sales performance falls below 95% of the target.
- 3The Board retains discretion over the total annual bonus payout, with the ability to reduce it based on quality objectives and performance.
- 4Introduction of the 2016 Total Shareholder Return Performance Share Program (TSR PSP), which links executive awards to BSX's TSR relative to the S&P 500 Healthcare Index over a three-year period.
- 5Establishment of the 2016 Free Cash Flow Performance Share Program (FCF PSP), incentivizing executives based on the company's free cash flow performance against its annual financial plan.
- 6Both performance share programs are designed as long-term incentives, with awards potentially ranging from 0% to 200% (TSR PSP) or 0% to 150% (FCF PSP) of target awards.
- 7Executive awards under these new plans are subject to a recoupment policy, including provisions for misconduct, gross dereliction of duty, financial restatements, and mandated clawback provisions under laws like the Dodd-Frank Act.